Shenzhen Key Laboratory of Microbial Genetic Engineering, Vascular Disease Research Center, College of Life Sciences and Oceanography, Guangdong Provincial Key Laboratory of Regional Immunity and Disease, Shenzhen University, China.
Arterioscler Thromb Vasc Biol. 2024 Dec;44(12):2560-2576. doi: 10.1161/ATVBAHA.124.321416. Epub 2024 Oct 3.
Pulmonary hypertension is a devastating vascular disorder characterized by extensive pulmonary vascular remodeling, ultimately leading to right ventricular failure and death. Activation of PDGF (platelet-derived growth factor) signaling promotes the hyperproliferation of pulmonary arterial smooth muscle cells (PASMCs), thus contributing to the pulmonary vascular remodeling. However, the molecular mechanisms that govern hyperproliferation of PASMCs induced by PDGF remain largely unknown, including the contribution of long noncoding RNAs (lncRNAs). In this study, we aimed to identify a novel lncRNA regulated by PDGF implicated in PASMC proliferation in pulmonary vascular remodeling.
RNA-sequencing analysis was conducted to identify a novel lncRNA named vessel-enriched lncRNA regulated by PDGF-BB (platelet-derived growth factor-BB; VELRP). Functional investigations of VELRP were performed using knockdown and overexpression strategies along with RNA sequencing. Validation of the function and potential mechanisms of VELRP was performed through Western blot, RNA immunoprecipitation, and chromatin immunoprecipitation assays.
We identified a novel vessel-enriched lncRNA with an increased response to PDGF-BB stimulus. VELRP was identified as an evolutionarily conserved RNA molecule. Modulation of VELRP in PASMCs significantly altered cell proliferation. Mechanistically, VELRP enhances trimethylation of H3K4 (histone H3 lysine 4) by interacting with WDR5 (WD repeat-containing protein 5), leading to increased expression of CDK (cyclin-dependent kinase) 1, CDK2, and CDK4 and consequent hyperproliferation of PASMCs. The pathological relevance of VELRP upregulation in pulmonary artery was confirmed using rat pulmonary hypertension models in vivo, as well as in PASMCs from patients with idiopathic pulmonary arterial hypertension. Specific knockdown of VELRP in smooth muscle cells using adeno-associated virus type 9 SM22α (smooth muscle protein 22α) promoter-shRNA-mediated silencing of VELRP resulted in a significant decrease in right ventricular systolic pressure and vascular remodeling in rat pulmonary hypertension model.
VELRP, as an lncRNA upregulated by PDGF-BB, mediates PASMC proliferation via WDR5/CDK signaling. In vivo studies demonstrate that targeted intervention of VELRP in smooth muscle cells can prevent the development of pulmonary hypertension.
肺动脉高压是一种破坏性的血管疾病,其特征为广泛的肺血管重塑,最终导致右心室衰竭和死亡。血小板衍生生长因子(PDGF)信号的激活促进肺动脉平滑肌细胞(PASMC)的过度增殖,从而导致肺血管重塑。然而,PDGF 诱导的 PASMC 过度增殖的分子机制在很大程度上仍不清楚,包括长链非编码 RNA(lncRNA)的贡献。在这项研究中,我们旨在鉴定一种新的由 PDGF 调控的 lncRNA,该 lncRNA参与肺血管重塑中的 PASMC 增殖。
进行 RNA 测序分析以鉴定一种新的 lncRNA,称为受 PDGF-BB(血小板衍生生长因子-BB)调控的血管丰富 lncRNA(VELRP)。通过使用敲低和过表达策略以及 RNA 测序来进行 VELRP 的功能研究。通过 Western blot、RNA 免疫沉淀和染色质免疫沉淀测定来验证 VELRP 的功能和潜在机制。
我们鉴定了一种新的血管丰富的 lncRNA,其对 PDGF-BB 刺激的反应增加。VELRP 被鉴定为一种进化上保守的 RNA 分子。在 PASMC 中调节 VELRP 显著改变了细胞增殖。在机制上,VELRP 通过与 WDR5(WD 重复蛋白 5)相互作用增强 H3K4(组蛋白 H3 赖氨酸 4)的三甲基化,导致 CDK(细胞周期蛋白依赖性激酶)1、CDK2 和 CDK4 的表达增加,从而导致 PASMC 的过度增殖。在体内大鼠肺动脉高压模型以及特发性肺动脉高压患者的 PASMC 中,使用腺相关病毒 9 SM22α(平滑肌蛋白 22α)启动子-shRNA 介导的 VELRP 沉默来特异性敲低平滑肌细胞中的 VELRP,证实了 VELRP 上调在肺动脉中的病理相关性。在大鼠肺动脉高压模型中,使用 adeno-associated virus type 9 SM22α(smooth muscle protein 22α)启动子-shRNA 介导的 VELRP 沉默特异性敲低平滑肌细胞中的 VELRP,导致右心室收缩压显著降低和血管重塑减少。
VELRP 作为一种由 PDGF-BB 上调的 lncRNA,通过 WDR5/CDK 信号介导 PASMC 增殖。体内研究表明,靶向干预平滑肌细胞中的 VELRP 可以预防肺动脉高压的发展。